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Abstract
Background and objective: Despite intensive colonoscopic surveillance, a substantial proportion of Lynch syndrome (LS)
patients develop colorectal cancer (CRC). The aim of this study was to characterize incident CRC in LS patients.
Methods: All patients diagnosed with incident CRC after start of colonoscopic surveillance were identified in the Dutch LS
Registry of 905 patients. A retrospective analysis of patient records was carried out for patient characteristics, survival, CRC
characteristics and findings of previous colonoscopy.
Results: Seventy-one patients (7.8%) were diagnosed with incident CRC. Median interval between incident CRC diagnosis
and previous colonoscopy was 23.8 (range 6.7–45.6) months. Median tumor diameter was 2.5 cm, and 17% of the tumors
were sessile or flat. Most patients (83%) had no lymph node metastases. There was no association between tumor size and
colonoscopy interval or lymph node status. Most patients (65%) had no adenomas during previous colonoscopy.
Two patients (2.8%) eventually died from metastatic CRC.
Conclusion: The high frequency of incident CRC in LS likely results from several factors. Our findings lend support to the
hypothesis of fast conversion of adenomas to CRC, as 65% of patients had no report of polyps during previous colonoscopy.
High-quality colonoscopies are essential, especially as tumors and adenomas are difficult to detect because of their frequent
non-polypoid appearance. Early detection due to surveillance as well as the indolent growth of CRC, as demonstrated by the
lack of lymph node metastases, contributes to the excellent survival observed.
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Key summary
Established knowledge
– Colonoscopic surveillance and the timely removal of adenomas have been shown to decrease the risk of
colorectal cancer in patients with Lynch syndrome.
– Possible reasons for developing cancer despite surveillance include missed tumors due to suboptimal colon
preparation, incomplete colonoscopy and incomplete removal of adenomatous tissue during previous
colonoscopy.
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– Until now, the adenoma and tumor characteristics and their contribution to colorectal cancer develop-
ment in Lynch syndrome patients have not been investigated in detail.
Significant findings of this study
– Most patients (65%) had no polyps during previous colonoscopy, which supports the hypothesis of fast
conversion of adenomas to cancer.
– The tumors were generally small (median diameter 2.5 cm), the majority of patients (83%) had no lymph
node metastases, and no association was found between screening interval and tumor size or tumor size
and lymph node metastases, all of which support the hypothesis of indolent growth of colorectal cancer in
Lynch syndrome.
– The frequent non-polypoid appearance of adenomas and tumors makes colonoscopic detection of these
lesions more difficult.
Introduction
Colorectal cancer (CRC) is one of the most common
cancers both in women and in men, with a yearly inci-
dence rate of more than 470,000 in Europe.1 In
approximately 3% of the cases, CRC can be attributed
to Lynch syndrome (LS).2 LS is caused by mutations in
one of the DNA mismatch-repair (MMR) genes
MLH1, MSH2, MSH6, and PMS2, and is inherited
in an autosomal-dominant manner.2
The prevention of CRC in LS patients is
based on regular colonoscopic surveillance and the
removal of adenomas. Current guidelines recommend
a screening interval between one and two years.2
However, despite intensive surveillance, the CRC inci-
dence rate in the LS population is as high as 13%
per 10 years.3 In Finland, where the surveillance inter-
val was set at two to three years, the cumulative risk of
CRC at 60 years was found to be 35% in men and 22%
in women.4
The high rate of incident CRC in LS patients under
surveillance has prompted several studies in the field.
Possible explanations for the development of CRC
include missed tumors due to suboptimal colon prepar-
ation, incomplete colonoscopy and incomplete removal
of adenomatous tissue during previous colonoscopy.5
Adhering to quality parameters such as documentation
of cecal intubation or prolonged withdrawal time can
increase adenoma detection rates.6 Furthermore, non-
polypoid adenomas are more frequently observed in LS
patients than in people at an average risk for CRC.7
Compared to regular polyps, these flat lesions might be
more difficult to detect. It has further been suggested
that the adenoma-carcinoma sequence is accelerated in
LS. In contrast to sporadic CRC where adenomas take
10 years to develop into cancer, in LS small adenomas
may develop into cancer even within a time frame of
one to two years. There is also some evidence that some
LS tumors might follow a non-polypoid pathway in
which invasive growth occurs directly from seemingly
normal mucosa.8
At the moment, it is unclear which factors contribute
the most to the development of incident CRC in LS
patients. Understanding how these cancers arise will
help to more effectively prevent CRC in this popula-
tion. To this end, we designed a study with data from a
prospectively collected database in Dutch LS patients.
We evaluated the features of incident CRC in LS
patients, both at the patient level and at tumor level.
We assessed patient survival after CRC diagnosis.
Finally, we examined the quality and findings of previ-
ous colonoscopy.
Methods
Study design and data collection
We analyzed prospectively collected data from the
Dutch LS Registry. The LS Registry coordinates sur-
veillance in hereditary CRC and was established in
1989. Its aims are to improve identification of heredi-
tary CRC, to promote participation in surveillance
programs, and to evaluate the screening protocol.
In clinical practice, reminders for surveillance are
sent to treating physicians and results of screening
are collected in the database. All patients who had
been registered before October 2012 and diagnosed
with incident CRC after registration and before
January 2017 were included. Some of the patients in
this cohort were included in an earlier cohort study
examining the associations between colonoscopy qual-
ity and incident CRC.5 Most of the patients in this
study were included in a recent European study3 that
compared the effect of various surveillance intervals
(one to three years) in LS patients on the incidence of
CRC and tumor stages. The study was approved by the
research committee of The Netherlands Foundation for
the Detection of Hereditary Tumors on July 1, 2017.
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All patients have given written permission for registra-
tion and anonymous evaluation of results. The study
protocol conforms to the ethical guidelines of the
Declaration of Helsinki.
Study cohort
Proven and obligate carriers of an MMR gene muta-
tion who developed CRC during the surveillance
period were included in the analysis. Patients with
CRC before registration who were diagnosed with a
new CRC after registration were also included, but
only CRC diagnosed after registration was included
in the analysis.
Collected data
For each patient, birth date, gender, gene defect, his-
tory and surgical treatment of CRC, date of last con-
tact or date of death and cause of death were recorded.
The histological grade, size, morphology, TNM stage,
and location of incident CRC were recorded. In case of
synchronous tumors, only the highest TNM stadium
was considered. Cancer was considered metastatic if
radiological evidence for metastases was available at
the time of surgery. The location of the tumor was
classified according to the colon segments cecum,
ascending colon, hepatic flexure, transverse colon, sple-
nic flexure, descending colon, sigmoid, and rectum.
The date of incident CRC diagnosis was defined
either as the date of colonoscopy where the tumor
was found or the date of surgery if colonoscopy date
was not recorded. For patients with multiple CRCs
during the surveillance period, information on the
first CRC was collected. Characteristics of previous
colonoscopy were noted as follows: colonoscopy date,
visualization of the whole colon, degree of bowel prep-
aration, whether polypectomy had been performed,
and the number, location, grade, size and morphology
of removed polyps.
Statistical methods
Frequencies are presented as absolute numbers and per-
centages. Continuous data are presented as mean
(standard deviation (SD)), and in the case of non-
normally distributed data as median (interquartile
(IQR)) range. The Shapiro-Wilk statistic for testing
normality was used. To test for an association between
two variables or a difference between two groups,
Pearson 2 test or Spearman’s rho were used depending
on the distribution of the data. To test for a difference
between three groups, a one-way analysis of variance
was used. The tests were considered statistically signifi-
cant if p< 0.05. All analyses were performed using IBM
SPSS Statistics for Mac, version 24.0.
Results
1. Patient characteristics
As of October 2012, a total of 905 patients had been
included in the registry. Seventy-one of these patients
(7.8%) had been diagnosed with incident CRC before
January 2017. Significantly more CRCs were found in
MLH1 and MSH2 mutation carriers (10.2% and 9.4%,
respectively) than in MSH6 mutation carriers (2.4%;
p¼ 0.001). No patients with PMS2mutation were diag-
nosed with incident CRC. The distribution of gene
mutations and number of incident CRCs is shown in
Table 1. The median follow-up time per patient starting
from registration and ending at last colonoscopy or at
the colonoscopy where interval CRC was diagnosed
was 12.6 (range 0.0–27.3) years. The cumulative
follow-up of patients per surveillance period and the
incidence of CRC per cumulative surveillance years is
shown in Table 2. Between the years 2000–2009 and
2010–2016, the incidence of CRC per cumulative
follow-up years decreased by 39.4%.
Twenty patients had been diagnosed with CRC prior
to registration. Nineteen patients had undergone a par-
tial colon resection. The median observation time
between registration and incident CRC diagnosis was
8.9 (range 0–20.2) years. Mean age at incident CRC
diagnosis was 51.6 (SD 10.3) years. Half of the patients
were male. The difference in age at CRC diagnosis
between the three groups of MMR mutation carriers
was not statistically significant. The mean screening
interval was 23.2 (SD 8.9) months, ranging from 6.7
to 45.6 months.
The median follow-up after CRC diagnosis was
6.0 (range 0.0–24.5) years. Ten patients died during
follow-up, two from metastatic CRC. The patients
who died from CRC were a male of 69 years and a





MLH1 315 32 (10.2)
MSH2 362 34 (9.4)
MSH6 205 5 (2.4)
PMS2 16 0 (0)
Total 905 71 (7.8)
CRC: colorectal cancer; MMR: mismatch repair.
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female of 61 years with screening intervals of 12.4
months and 21.6 months, respectively. The male patient
had a T3N2 tumor, and the female patient had a T2N0
tumor. The male survived for 2.5 years and the female
for 1.5 years after surgery. The patient characteristics
are summarized in Table 3.
2. Characteristics of incident CRC
(a) Tumor staging
A total of 76 tumors were discovered in 71 patients.
Most tumors were located in the proximal colon, the
cecum being the most common location.
Tumor stage according to the TNM classification
was available for 70 patients: Eighteen patients
had T1, 26 patients had T2, 25 patients had T3,
and one patient had T4. One patient had a T3 or
T4 tumor. Fifty-nine patients had no lymph node
metastases, 11 had N1, and one patient had N2.
No patients had distant metastases at the time of
diagnosis.
(b) Tumor size and morphology
Tumor diameter at histopathology was available
for 69 tumors. The median diameter was 2.5 cm
(range 0.8–8.0); 55.1% was smaller than 3.0 cm, and
15.9% had a diameter of  5.0 cm. Forty-six tumors
were described as expansive lesions, and 13 had sessile
or flat morphology. Pathology reports described aden-
omatous tissue at the site of 13 tumors. There was no
association between the length of screening interval and
tumor diameter, or between tumor size and lymph node
status. Tumor characteristics are summarized in
Table 4.
3. Quality and outcome of previous colonoscopy
For 66 patients, information was available on the
colonoscopy preceding incident CRC diagnosis.
Suboptimal colon preparation was described in two
cases. Full colon visualization was not performed in
three cases. Two of these patients had undergone a
barium enema or computed tomography-colography,
and for one patient it was unclear whether a barium
enema had been performed. All three patients devel-
oped subsequent CRC in the previously unvisualized
part of the colon.
Polypectomy was performed in 22 patients during
their previous colonoscopy; a total of 34 polyps were
detected and removed. Most patients had one polyp
removed. The median diameter of the polyps was
3mm (range 1–14mm).
Table 2. Follow-up of the Lynch syndrome cohort and incidence of CRC per surveillance period.
Period (years)
1989–1994 1995–1999 2000–2004 2005–2009 2010–2016
Patients with FU colonoscopies 176 443 650 807 742
FU per patient,
years (median, IQR)
1.8 (1.1–2.4) 3.9 (2.1–5.0) 5.0 (3.0–5.0) 5.0 (1.1–5.0) 5.8 (4.9–6.4)
Cumulative FU
per period (years)
309 1542 2563 3517 3967
Number of interval CRC 2 7 16 26 20
Incidence interval CRC
per cumulative FU years
0.0065 0.0045 0.0062 0.0074 0.0050
CRC: colorectal cancer; FU: follow-up; IQR: interquartile range.
Table 3. Patient characteristics.
N¼ 71
Median Range




Age at registration (years) 42.7 11.1
Age at diagnosis (years) 51.6 10.3
(range 26.1–76.3)
N %
Gender (male) 36 50.7
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Twenty-one polyps had low-grade dysplasia, one
had high-grade dysplasia, and six were hyperplastic.
Of the adenomatous polyps, 12 were described as sessile
or flat, and one was described as pedunculated.
Serrated polyps were not described in any of the colon-
oscopy or histopathology reports.
Incident CRC was discovered at the colon segment
where previous polypectomy had been performed in 10
of the 22 patients. The findings are summarized in
Table 5.
Table 5. Quality and findings of previous colonoscopy.
N¼ 66
Mean SD (range)
Surveillance interval (months)a 23.2 8.9 (6.7–45.6)
N %
Quality of bowel preparation
Clean 63 95.5










Number of polyps removed
Total 34
Patients with one polyp 13 59.1
Patients with two polyps 7 31.8
Patients with three polyps 1 4.5
Patients with four polyps 1 4.5
Median (range) 1 (1–4)
Grade polyps
Low-grade dysplasia 21 61.8




Proximal colon 16 47.1









Size polyps (mm), median (range)b 3 (1–14)
<5 mm 14 50.0
5 mm 9 32.1
Unknown 5 17.9
aAvailable for 65 patients.
bAdenomatous polyps, N¼ 28.
Table 4. Features of incident CRC.
N¼ 76a
N %
Patients with tumor at colonic segment
with previous polypectomy (N¼ 71)
10 14.1
Patients with tumor in previously
unvisualized colon (N¼ 71)
3 4.2
Adenomatous tissue at tumor site 13 17.1
Location of tumor
Proximal colon 57 75.0
Cecum 21 27.6
Ascending colon 16 21.1
Hepatic flexure 10 13.2
Transverse colon 10 13.2
Distal colon/rectum 19 25.0
Splenic flexure 4 5.3
Descending colon 3 3.9
Sigmoid colon 8 10.5
Rectum 4 5.3
Histological grade
Well differentiated 7 9.2
Moderately differentiated 43 56.7























aFive patients had two synchronous tumors.
bOnly highest stage CRC considered per patient.
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Discussion
Despite intensive colonoscopic surveillance, 7.8% of LS
patients in the Dutch LS Registry developed CRC.
Incident CRC was more often found in MLH1 and
MSH2 mutation carriers compared to MSH6 mutation
carriers, and no incident CRC was diagnosed in PMS2
mutation carriers. These results are in agreement with
other previously published studies.9,10 MSH6 mutation
carriers generally develop cancer at a later age than
patients with MLH1 or MSH2 mutations.11 However,
as our cohort included only five MSH6 mutation car-
riers with incident CRC, we lacked statistical power to
detect a difference in age among the three groups.
More than 60% of the patients had T1/2 disease, less
than one-fifth had lymph node metastases, and no
patients had distant metastases at the time of diagnosis.
Accordingly, the overall survival in our cohort
exceeded 85% with less than 3% dying from metastatic
CRC. Similar survival figures have been previously
reported by Møller et al.11 Early diagnosis probably
contributes to the excellent survival.
Good-quality surveillance colonoscopies are import-
ant in preventing CRC in LS. Poor bowel preparation
is associated with a reduced detection of small or flat
lesions.12 Visualization of the entire colon is necessary
because of the high frequency of LS CRC in the prox-
imal colon. Furthermore, residual adenomatous tissue
after incomplete polypectomy can develop into cancer.
In our cohort, 4% of patients developed CRC in pre-
viously unvisualized segments of the colon, and almost
50% of patients had CRC in the same colonic segment
where polypectomy had previously been performed.
Other factors such as sedation practice and with-
drawal time can affect the quality of the surveillance
colonoscopy.6 Given that data for this study were
gathered over a 30-year period, information on
modern parameters assessing the quality of the colon-
oscopy was largely missing from the reports. Even so,
it seems that colonoscopy quality has been improving
in recent years as the incidence of CRC per cumulative
follow-up years decreased by almost 40% from
2000–2009 to 2010–2016.
The morphology of colorectal neoplasms in LS may
differ from that in sporadic CRC. Most tumors in our
cohort were exophytic similar to non-LS CRCs, but
nearly one-fifth were sessile or flat and at least one-
half had a diameter of less than 3 cm. In contrast, flat
cancers represented 10% of all CRC found in 1026
consecutive colonoscopies in a series of patients that
also included patients with a family history of cancer.13
Almost one-half of the polyps in the previous colon-
oscopy were also described as sessile or flat. Previous
research has reported on a high frequency of non-
polypoid lesions in LS.7 An example of such a lesion
in an LS patient is shown in Figure 1. Besides being
more difficult to detect, flat adenomas have been asso-
ciated with a higher degree of malignant potential.
Invasive cancer is found in non-polypoid lesions at a
smaller size as compared with polypoid lesions.13,14
High-grade dysplasia14,15 and invasion of the submuco-
sal layer14 are also more often reported in flat lesions
than in polypoid lesions.
It has been suggested that the development of incident
CRC in LS could in some cases follow a non-polypoid
pathway where invasive growth occurs directly from
seemingly normal mucosa8 or via the serrated neoplasia
pathway.16 However, the role of adenomas in LS CRC is
strongly supported as they are more frequently found in
MMR gene mutation carriers,17 and the efficiency of
screening in LS is based on the removal of adenomas.18
In our cohort, some pathology reports described aden-
omatous tissue at the cancer site, and incident CRCs
were found at the site of previous polypectomies. As
we cannot draw any hard conclusions from our data
regarding the origin of CRC in our cohort, the role of
non-polypoid pathways in LS CRC development needs
to be further studied.
Besides morphological differences, colorectal neo-
plasms in LS patients might employ another method
to escape detection. The adenoma-carcinoma sequence
seems accelerated in LS. In our cohort, 65% of patients
with incident CRC had no report of polyps during pre-
vious colonoscopy. Similarly, in another cohort, 58%
of patients with incident CRC had no pathologic find-
ings during previous surveillance colonoscopy.19
Furthermore, shorter surveillance intervals do not
lead to a reduced incidence of CRC.3 Some adenomas
are probably able to develop and undergo malignant
change in the time period between two surveillance
colonoscopies.
Another feature of LS CRC is its slow growth. In the
2017 study by Engel et al., no association was found
Figure 1. Non-polypoid adenoma of 15 mm in the ascending colon
in a Lynch syndrome patient with MLH1 mutation.
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between screening interval and tumor stage.3 In our
cohort, the tumors were generally small and most
were T1/T2–N0, probably partly because of the short
surveillance intervals. However, there was no associ-
ation between surveillance interval and tumor size or
tumor size and the presence of lymph node metastases.
The strength of this study was the analysis of pro-
spectively collected data from a large database span-
ning almost three decades. However, the length of the
data collection period was also one of the limitations.
The quality of reporting in colonoscopy and pathology
reports was inconsistent, as current quality consider-
ations regarding colon preparation or visualization
have not been implemented until recently.
This study has several implications for clinical prac-
tice. From the patient’s perspective, incident CRC can
be regarded as a phenotype of LS. The 10-year cumu-
lative risk of developing incident CRC is 9%–13% in
LS patients.3 This means that 45%–65% of LS patients
will develop CRC during the surveillance period
between 25 and 75 years. As mortality from incident
CRC was only 2.8%, the risk of dying from CRC
during the surveillance period is only 1.26%–1.82%.
With improving quality of screening colonoscopies,
these numbers can be expected to decline. Patients
should be aware that adherence to screening programs
is required, as patient-related delayed diagnosis of CRC
was the cause of death in 80% of cases in a study on LS
patients.4
From the physician’s perspective, paying attention
to the quality of the screening colonoscopies is essen-
tial. In case of an incomplete colonoscopy, a repeat
examination should be scheduled. Quality parameters
such as the Boston Bowel Preparation Scale,20 record-
ing of withdrawal time, confirming cecum intubation,
and the Leiden Quality Score21 may help to improve
the success of screening colonoscopies. Furthermore,
the frequently observed small and flat morphology of
adenomas and CRC in LS patients pose an additional
challenge to the colonoscopist.
Conclusion
The high rate of incident CRC in LS likely results from
multiple factors. Our findings support the hypothesis of
fast conversion of adenomas to cancer in LS, but to
what extent non-polypoid pathways play a role needs
to be studied further. The often non-polypoid appear-
ance of colorectal lesions makes them more difficult to
detect. Incomplete colonoscopies and the incomplete
removal of adenomatous tissue during polypectomy
contribute to development of incident CRC. In order
to better understand tumor development in LS, a pro-
spective analysis of adenoma and CRC morphology
would be helpful.
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